INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 157 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 2.78 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $102 | +142.9% | 5,510 | +46.0% | 0.00% | – |
| Q2 2023 | $42 | -8.7% | 3,774 | +9.7% | 0.00% | – |
| Q1 2023 | $46 | -6.1% | 3,439 | -13.0% | 0.00% | – |
| Q4 2022 | $49 | -99.9% | 3,951 | 0.0% | 0.00% | -100.0% |
| Q3 2022 | $55,000 | +1.9% | 3,951 | +1.5% | 0.00% | 0.0% |
| Q2 2022 | $54,000 | -18.2% | 3,891 | -4.6% | 0.00% | 0.0% |
| Q1 2022 | $66,000 | -76.8% | 4,078 | -9.6% | 0.00% | -85.7% |
| Q1 2020 | $284,000 | -51.3% | 4,512 | -4.0% | 0.01% | -36.4% |
| Q4 2019 | $583,000 | +100.3% | 4,701 | +7.3% | 0.01% | +83.3% |
| Q3 2019 | $291,000 | -17.8% | 4,382 | -1.4% | 0.01% | -25.0% |
| Q2 2019 | $354,000 | -4.8% | 4,445 | +33.6% | 0.01% | -11.1% |
| Q1 2019 | $372,000 | +15.5% | 3,328 | +4.1% | 0.01% | 0.0% |
| Q4 2018 | $322,000 | +15.0% | 3,196 | -4.2% | 0.01% | +28.6% |
| Q2 2018 | $280,000 | +18.6% | 3,337 | -12.9% | 0.01% | +16.7% |
| Q1 2018 | $236,000 | +12.9% | 3,831 | +6.9% | 0.01% | 0.0% |
| Q4 2017 | $209,000 | -46.5% | 3,584 | +11.1% | 0.01% | -53.8% |
| Q2 2017 | $391,000 | +44.3% | 3,226 | +34.6% | 0.01% | 0.0% |
| Q1 2017 | $271,000 | -14.8% | 2,396 | -18.1% | 0.01% | -7.1% |
| Q4 2016 | $318,000 | -26.2% | 2,927 | +11.7% | 0.01% | -44.0% |
| Q3 2016 | $431,000 | +4.4% | 2,620 | +0.0% | 0.02% | +4.2% |
| Q2 2016 | $413,000 | +70.7% | 2,619 | +39.0% | 0.02% | 0.0% |
| Q1 2016 | $242,000 | -6.9% | 1,884 | +8.4% | 0.02% | -25.0% |
| Q4 2015 | $260,000 | -15.9% | 1,738 | -6.6% | 0.03% | 0.0% |
| Q3 2015 | $309,000 | -30.2% | 1,861 | +1.3% | 0.03% | -27.3% |
| Q2 2015 | $443,000 | +5.0% | 1,837 | +22.6% | 0.04% | -15.4% |
| Q1 2015 | $422,000 | +99.1% | 1,498 | +10.1% | 0.05% | +57.6% |
| Q4 2014 | $212,000 | -33.8% | 1,361 | +0.5% | 0.03% | -31.2% |
| Q3 2014 | $320,000 | +0.6% | 1,354 | +0.8% | 0.05% | 0.0% |
| Q2 2014 | $318,000 | +30.9% | 1,343 | +82.2% | 0.05% | +14.3% |
| Q1 2014 | $243,000 | – | 737 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $14,787,000 | 2.73% |
| DeepCurrents Investment Group LLC | 416,800 | $9,620,000 | 0.33% |
| DUALITY ADVISERS, LP | 105,668 | $2,439,000 | 0.21% |
| EULAV Asset Management | 335,000 | $7,732,000 | 0.21% |
| Virtus ETF Advisers LLC | 19,375 | $447,000 | 0.19% |
| Hennion & Walsh Asset Management, Inc. | 135,214 | $3,121,000 | 0.19% |
| PDT Partners, LLC | 110,592 | $2,552,000 | 0.18% |
| KETTLE HILL CAPITAL MANAGEMENT, LLC | 70,256 | $1,622,000 | 0.16% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $3,896,000 | 0.12% |
| WOODWARD DIVERSIFIED CAPITAL, LLC | 8,939 | $206,000 | 0.12% |